secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001437749-25-008137
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q4 2024 revenue $11.6M (+59% YoY); net loss narrows to $0.6M
------------------------------------------------------------------------

- Record product revenue of $11.6M in Q4 2024, up 59% from Q4 2023; 16th consecutive quarter of sequential growth.
- Net loss improved to $0.6M ($0.02/share) vs $2.3M loss ($0.09/share) in Q4 2023.
- Closed transformational acquisition of Increlex (relaunched Jan 2025) and acquired Galzin; both tracking ahead of expectations.
- Positive pivotal study for ET-600; NDA submission planned April 2025; ET-400 launch inventory ready with PDUFA May 28.
- Cash balance $14.9M at Dec 31, 2024; company expects sequential revenue growth to continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925008137/0001437749-25-008137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925008137/eton20250305_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-008137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer